{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T05:26:43Z","timestamp":1771046803525,"version":"3.50.1"},"reference-count":7,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T00:00:00Z","timestamp":1701907200000},"content-version":"vor","delay-in-days":371,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.ymthe.2022.11.006","type":"journal-article","created":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T16:35:08Z","timestamp":1669134908000},"page":"3508-3509","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Hemophilia \u201cA\u201d gene therapy: Lost in translation"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4230-745X","authenticated-orcid":false,"given":"Thierry","family":"VandenDriessche","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marinee K.","family":"Chuah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2022.11.006_bib1","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1016\/j.ymthe.2022.09.020","article-title":"First conditional marketing authorization approval in the European Union for hemophilia \"A\" gene therapy","volume":"30","author":"VandenDriessche","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2022.11.006_bib2","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1056\/NEJMoa2113708","article-title":"Valoctocogene roxaparvovec gene therapy for hemophilia A","volume":"386","author":"Ozelo","year":"2022","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2022.11.006_bib3","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/hae.14391","article-title":"Persistence of haemostatic response following gene therapy with valoctocogene roxaparvovec in severe haemophilia A","volume":"27","author":"Pasi","year":"2021","journal-title":"Haemophilia."},{"key":"10.1016\/j.ymthe.2022.11.006_bib4","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1056\/NEJMoa2104205","article-title":"Multiyear factor VIII expression after AAV gene transfer for hemophilia A","volume":"385","author":"George","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2022.11.006_bib5","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1016\/j.ymthe.2022.07.005","article-title":"IL-15 blockade and rapamycin rescue multifactorial loss of factor VIII from AAV-transduced hepatocytes in hemophilia A mice","volume":"30","author":"Butterfield","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2022.11.006_bib6","doi-asserted-by":"crossref","first-page":"e722","DOI":"10.1016\/S2352-3026(22)00300-3","article-title":"Should patients with haemophilia receive gene therapy?","volume":"9","author":"VandenDriessche","year":"2022","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.ymthe.2022.11.006_bib7","doi-asserted-by":"crossref","first-page":"3570","DOI":"10.1016\/j.ymthe.2022.11.001","article-title":"Vector genome loss and epigenetic modifications impact long-term transgene expression of AAV5 vectors produced in mammalian HEK293 and insect Sf cells","volume":"30","author":"Handyside","year":"2022","journal-title":"Mol. Ther."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001622006645?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001622006645?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:07:24Z","timestamp":1761502044000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001622006645"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":7,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S1525001622006645"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2022.11.006","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hemophilia \u201cA\u201d gene therapy: Lost in translation","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2022.11.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}